Navigation Links
Tandem Diabetes Care Acquires Select Patents and Patent Applications from Smiths Medical
Date:2/1/2013

SAN DIEGO, Feb. 1, 2013 /PRNewswire/ -- Tandem Diabetes Care, Inc. ("Tandem") announced today that it has acquired ownership from Smiths Medical ASD, Inc. of over 23 U.S. patents and patent applications relating to the treatment of diabetes. As part of this transaction, Tandem has also obtained a license to 28 other U.S. patents and patent applications owned by Smiths Medical. This license affords Tandem exclusive access to technologies useful for future product development in the field of ambulatory infusion pumps and related software and accessories for the treatment of diabetes. These patents and patent applications complement Tandem's growing portfolio of intellectual property related to the company's novel technologies.

About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a privately held company dedicated to advancing the management of diabetes through novel technologies. The Company offers a comprehensive, user-centric and integrated approach to product design, development, and customer care. Tandem Diabetes Care is based in San Diego, Calif.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslim.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetesCorp.

Tandem Diabetes Care is a registered trademark of Tandem Diabetes Care, Inc.


'/>"/>
SOURCE Tandem Diabetes Care, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Pharmaceutical Company Achieves Positive In-Vitro Testing Results Diabetes Drug
2. In Preventing Diabetes-Related Heart Disease, Blood Pressure and Cholesterol Targets are Higher Priorities than Blood Sugar
3. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
4. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
5. Genalyte Awarded $500,000 SBIR Grant To Develop Multiplexed Assays For Early Detection And Monitoring Of Type 1 Diabetes
6. ObeTherapy Announces the Publication of Results Obtained with one of its Lead Compounds on a New Target for the Treatment of Obesity and Type II Diabetes
7. High Degree of Disease Prevalence Sustains Diabetes Diagnostics Market in Europe, Finds Frost & Sullivan
8. Novo Nordisk Supports Four San Francisco-based Organizations In Fight Against Diabetes
9. LEVEL Lifes "FUEL A Cure" Diabetes Contest
10. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
11. Diabetes Care Devices Market to 2018 - Integrated Insulin Pumps with Continuous Glucose Monitoring Technology to Add a New Dimension to Diabetes Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):